Assessing Market Potential Leveraging a Scientific Approach to Assess the Clinical Landscape and Market Opportunity for Three Biologic Agents in the Heme Malignancy Space The Challenge An emerging oncology company with a robust pipeline of agents was seeking to evaluate the US oncology/hematology landscape across three preclinical assets, in furtherance ...

Medical Science Liaisons are key points of contact at point of care and with payers to communicate key scientific information.  To provide its client with a strong and informed MSL team, IP developed customized training solutions to ensure a cohesive approach to stakeholder engagement. 

Conferences provide an important opportunity to engage with multiple stakeholders as large groups or in smaller 1:1 settings.  IP leveraged its expertise to coordinate multiple types of engagements and gather key insights for its client.

In order to develop an engagement plan for a stakeholder community which was growing and complex, IP identified and engaged multiple tiers of opinion leaders ensuring the client was able to reach a broad customer audience.

Guideline Advocacy Strategy IP leveraged its Medical Affairs expertise and relationships with key opinion leaders to support a clinician-led effort to draw attention to treatment for a rare disease, resulting in the publication of new clinical practice guidelines. The Challenge The client had launched a therapy for the treatment of ...

IP leveraged its Medical Affairs expertise and experience supporting more than 70 submissions to key oncology clinical practice guidelines to advocate for the inclusion of a test that predicts the benefit of therapy, resulting in broad and appropriate access for patients. 

Engaging Community and Academic Physicians in Preparation for Product Launch The Challenge A biopharmaceutical company has in-licensed a new drug that gained FDA approval soon after the agreement went into effect. They want to build relationships with academic medical centers and community oncology practices to engage and educate key decision-makers relative ...

Understanding the Patient Journey and Pain Points in Diagnosis The Challenge A biopharmaceutical company wants to shift patients indicated for their soon to be approved treatment from allergists/immunologists to oncologists across community practices. The IP Solution IP supported the development and execution of a three-part advisory ...

Collecting KOL Insights Into Trial Design The Challenge A biopharmaceutical company with a novel targeted treatment in phase 1/2A wants to better understand critical success factors for their drug and obtain input on the design of the next phase of clinical trials that will satisfy both FDA regulators and physicians.  Two ...

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.